EGFR and non-small cell lung carcinoma: Molecular targeting using epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs), including first‐generation (1G) TKIs, such as gefitinib and erlotinib,1, 2, 3, 4 second‐generation (2G) TKIs, such as afatinib and dacomitinib,5, 6, 7, 8 and the third‐generation (3G) TKI, osimertinib,9, 10 have become the first‐line treatment for patients with advanced non‐small‐cell lung cancer (NSCLC) who harbor activating EGFR mutations (EGFRm+).11, 12